ACOSOG Z1031: Neoadjuvant Comparison between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Rich Stage 2/3 Breast Cancer ACOSOG Z1031 investigators identified 2 data sets that will help inform the design of larger adjuvant endocrine trials. One finding will help in the selection of agents: Letrozole, anastrozole, and exemestane showed no difference in efficacy in the neoadjuvant setting for postmenopausal women with estrogen receptor–rich (Allred 6-8) clinical stage 2/3 breast cancer. The other finding will help in patient selection: Patients with pretreatment intrinsic subtype luminal B had more favorable preoperative endocrine prognostic in - dex scores than patients with subtype luminal A. This finding suggests that because approximately one-third of women with subtype luminal A may be able to avoid chemo therapy, they are not suitable for larger adjuvant en docrine trials. Ellis M, et al. Abstract S1-2.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor– Positive Breast Cancer Evaluating the results of 3 Eastern Cooperative Oncology Group trials— E1199, E5188, and E3189—investigators identified a strong relationship between body mass index (BMI) and disease-free survival (DFS) and overall survival (OS). They found that a BMI >30 kg/m2 at diagnosis is associated with significantly inferior DFS and OS in women with hormone receptor–positive operable breast cancer treated with adjuvant chemotherapy. The investigators concluded that their findings imply that factors associated with obesity may predispose this subset of patients to recurrence. Sparano JA, et al; for the Southwest Oncology Group; Cancer and Leukemia Group B; North Central Cancer Treatment Group. Abstract S2-1.
To sign up for our newsletter or print publications, please enter your contact information below.
